Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy.

MLA

Yaghoubi, Sajad, et al. “Potential Drugs Used in the Antibody–drug Conjugate (ADC) Architecture for Cancer Therapy.” Journal of Cellular Physiology, vol. 235, no. 1, Jan. 2020, pp. 31–64. EBSCOhost, https://doi.org/10.1002/jcp.28967.

APA

Yaghoubi, S., Karimi, M. H., Lotfinia, M., Gharibi, T., Mahi, B. M., Kavi, E., Hosseini, F., Sineh Sepehr, K., Khatami, M., Bagheri, N., & Abdollahpour, A. M. (2020). Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. Journal of Cellular Physiology, 235(1), 31–64. https://doi.org/10.1002/jcp.28967

Chicago

Yaghoubi, Sajad, Mohammad Hossein Karimi, Majid Lotfinia, Tohid Gharibi, Birjand, Motahare Mahi, Esmaeil Kavi, Fahimeh Hosseini, et al. 2020. “Potential Drugs Used in the Antibody–drug Conjugate (ADC) Architecture for Cancer Therapy.” Journal of Cellular Physiology 235 (1): 31–64. doi:10.1002/jcp.28967.